Chiaramente, ogni formato ha i propri vantaggi e svantaggi comprare keflex senza ricetta per effettuare un acquisto, non è necessario fornire la prescrizione medica.

Cb03u000177p

Bronchoscopy in Nonresolving
pneumonia (VAP), the mortality rate in patients who had a rising score at 72 h, particularly if this score was ⱖ 20,was nearly 100% (Table 22).
Michael S. Niederman, MD, FCCP (CHEST 2000; 117:212S–218S)
Defining Pneumonia Resolution Abbreviations: APACHE ⫽ acute physiology and chronic
The resolution of nosocomial pneumonia can be de- health evaluation; CPIS ⫽ clinical pulmonary infection score; fined clinically or microbiologically, but presumably a PSB ⫽ protected-specimen brush; VAP ⫽ ventilator-associated clinical nonresponse will the prompt consideration of bronchoscopic evaluation. Definable clinical end pointsinclude the following: resolution of all signs and symptoms of infection; improvement in all signs and symptoms of in evaluating and managing patients with nosocomial infection; slow or delayed resolution of signs and symp- pneumonia who are not responding to initial antibiotic toms; relapse after initial infection (presumably represent- therapy. This discussion examines whether the informa- ing recurrent infection); progression of signs and symp- tion provided by bronchoscopy has value in this setting, as toms (rapid or gradual); superinfection that clinically well as whether the concept of using bronchoscopy for the resembles delayed resolution, progression, or relapse, but nonresponding patient is a logical one.
is characterized by these clinical findings in conjunction Importantly, serial bronchoscopy is generally per- with the microbiological finding of an organism not formed while the patient is receiving antibiotic therapy.
present at the onset of pneumonia; and, finally, death due Such therapy can reduce the yield and accuracy of quan- to unresolved infection, the ultimate outcome of a lack of titative cultures of respiratory secretions. The presump- response to therapy. Measurements to define these clini- tion for using serial cultures in the nonresponding patient cal end points include assessment of the following: fever, is that bacteria are present that have not been eliminated sputum purulence, leukocytosis, oxygenation, radiographic by currently administered antibiotics. Moreover, these improvement, duration of organ failure, duration of me- organisms can be identified early enough so that changes chanical ventilation, and need for changes in antibiotic in therapy will improve the outcome in these patients.
One way to assess the clinical resolution of pneumonia is to combine a number of clinical findings into a scoring Can Clinical Features Be Used to Predict system, such as the clinical pulmonary infection score the Likelihood of a Nonresponse to (CPIS) of Pugin et al30 Using a modification of this system, Garrard and A'Court131 measured the CPIS on a dailybasis in 83 patients with nosocomial pneumonia. The CPIS A number of clinical findings have been identified as was used to diagnose pneumonia if the score was ⱖ 6 risk factors for mortality from nosocomial pneumonia. If a (highest possible score, 10), based on the assessment of patient has a multitude of these features and is not five variables, each with a score range of 0 to 2. These responding to initial antibiotic therapy, the nonresponse variables were the following: temperature, WBC count, may be the inevitable outcome of serious systemic illness purulence of secretions, oxygenation, and extent of radio- and comorbidity. Serial bronchoscopic data are unlikely to graphic infiltrates. The CPIS was observed to increase reduce the expected high mortality rate in such a popula- progressively from a baseline value of ⬍ 6 to a value of ⬎ 6 tion. Such risk factors, identified in multivariate analysis, over the 2 days preceding the day of diagnosis and included the following: prolonged duration of ventilation, initiation of antibiotic therapy.30 Once therapy was begun, coma on admission, creatinine levels ⬎ 1.5 mg/dL, and the CPIS fell gradually over the next 9 days, generally transfer to the ICU from another ward67; the presence of dropping below 6 by the fifth day. When the CPIS did not certain high-risk pathogens, abnormal bilateral radio- fall, clinical deterioration was usually due to infection with graphic findings, inappropriate initial therapy, age ⬎ 60 years, and an ultimately terminal underlying condition62; Resolution also can be defined by bacteriologic end shock, inappropriate initial therapy, and rapidly fatal un- points that are based on the assessment of serial qualitative derlying illness44; prior antibiotic therapy128; infection with cultures of respiratory secretions. Microbiological eradica- a resistant organism, particularly Pseudomonas aeruginosa tion is defined by the elimination of the original pathogen or Staphylococcus aureus129; multiple systems organ fail- from the culture of the secretion, usually sputum. Persis- ure, nonsurgical primary diagnosis, late-onset infection tence is defined by a failure to eliminate the organism.
with a high-risk pathogen, and prophylaxis for intestinal Reinfection refers to elimination of the organism, followed bleeding with a pH-elevating agent.127 More recently, by its return, and superinfection refers to the appearance Rello et al130 observed that if acute physiology and chronic of a new organism in the culture. Quantitative microbiol- health evaluation (APACHE) II scores are followed seri- ogy cultures of respiratory secretions obtained broncho- ally after the onset of P aeruginosa ventilator-associated scopically or nonbronchoscopically also can be used todefine the resolution of nosocomial pneumonia.
*From the Division of Pulmonary and Critical Care Medicine, Garrard and A'Court131 used serial quantitative cultures Winthrop University Hospital, Mineola, NY.
of nondirected, nonbronchoscopic lung specimens ob- Evidence-Based Assessment of Diagnostic Tests for Ventilator-Associated Pneumonia Table 22—Studies Defining Risk Factors for Mortality in VAP*
Univariate Predictors No. of Patients With NP Resistant Bacteria Risk Craven et al67/1986 Duration of Vent, creatinine ⬎ 1.5, respiratory failure, and Celis et al62/1988 120 (84 resp failure) 36.6 (47.6 if resp failure) Age ⬎ 60, service UF illness, High-risk organism prior ABTC, high-risk organism, bilateral infiltration, shock, Rx, Age ⬎ 60 yr Torres et al44/1990 UF illness, inappropriate Rx, prolonged ICU, shock, Rello et al47/1991 20/91 with Haemophilus 30 (none died from influenzae (vent) H influenzae Rello et al128/1993 Age ⬎ 45 yr, corticosteroid Yes, high-risk pathogen Rx, shock, VAP onset ⬎ 9 days, COPD, prior ABTC Malangoni et al129/1994 2/3 failures developed resistance during Rx,ESP withP aeruginosa *Rx ⫽ treatment; ABTC ⫽ antibiotic; UF ⫽ ultimately fatal; NP ⫽ nosocomial pneumonia; vent ⫽ receiving ventilation; resp ⫽ respiratory.
tained by lavage from patients receiving ventilation who sodes in 30 patients in whom there was clinical suspicion have nosocomial pneumonia and correlated the findings of pneumonia and found borderline results (102 to 103 with serial measurement using the CPIS. Using a 14-gauge cfu/mL) with the initial cultures. Patients had repeat tracheal suction catheter with 20 mL normal saline solu- bronchoscopy within 72 h if the suspicion of pneumonia tion, the authors evaluated 89 episodes of nosocomial in 83 persisted and if patients were not given antibiotics. In 12 patients by using alternate-day sampling and quantitative episodes, the same organism was isolated on the repeat cultures of respiratory secretions. Culture counts rose bronchoscopy, but the concentration was then ⬎ 103 during the 2 days preceding the clinical onset of pneumo- cfu/mL and antibiotics were given. In 22 episodes, pneu- nia and fell rapidly with the initiation of therapy. Patients monia was excluded as a diagnosis. The mortality rate in showing a clinical response to therapy had a rapid fall in the eight patients having a positive culture finding on colony counts by 24 h, in most instances, and usually no repeat bronchoscopy was 75% (6 patients), which was later than 48 to 72 h, unless there was a lack of response significantly higher than the mortality rate in the 18 to treatment. The patients who had no response to patients with a negative culture finding on repeat bron- treatment usually had P aeruginosa pneumonia; these choscopy (22%; 4 patients; p ⬍ 0.04). Serial bronchoscopy patients had a persistence of colony counts of ⬎ 10,000 can identify pneumonia patients who cannot contain a cfu/mL and a high mortality rate. Serial quantitative bacterial challenge or who had a prior false-negative cultures correlated well with clinical response and mortal- culture finding. The high mortality rate may be related to ity, with the counts of those patients responding falling the delayed initiation of antibiotic therapy after an initial rapidly. This microbiological pattern was analogous to the false-negative culture result.
clinical findings, as reflected by the CPIS. Nonresponse to Montravers et al32 studied the results of cultures with therapy was not predicted more accurately by microbio- specimens gathered using the serial PSB method in 76 logical findings than by clinical findings. While a microbi- patients with VAP. A clinical suspicion of pneumonia in ological nonresponse could be defined at 24 to 72 h, the enrolled patients was confirmed by a bacteria count of recognizing a clinical nonresponse generally took longer.
ⱖ 103 cfu/mL in a sample. The clinicians' initial antibiotic Serial bronchoscopy also has been used to determine choice was modified on the basis of bronchoscopy results.
whether a patient is not responding to initial therapy, and All patients had a second bronchoscopy 3 days after entry if so, why. Dreyfuss et al60 collected data using a serial into the study. The clinical outcome and serial microbio- protected-specimen brush (PSB) technique for 34 epi- logical data were compared, with clinical outcomes classi- CHEST / 117 / 4 / APRIL, 2000 SUPPLEMENT Table 23—Studies of Repeat Bronchoscopy During the Course of Suspected VAP*
When Bronchoscopy Repeated Impact on Outcome Montravers et al32/1993 PSB after 3 d therapy Defining bacteriologic failure at day 3 16 with ⬍ 103 cfu/mL did not prevent high mortality 9 with ⬎ 103 cfu/mL 7% failure rate if sterile at day 3 56% failure ifrepeat ⬎ 103 cfu/mL Dreyfuss et al60/1993 Mean, 2.7 d after first therapy 12 had pneumonia on repeat Higher mortality in group with ⫹ repeat bronchoscopy, delay in adequate Rx *See Table 22 for abbreviation.
†With 34 episodes. PSB method yielded borderline cultures on first test; there was no effective RX for these organisms.
fied as improved, relapse, or failure. Bacteriologic out- study), the mortality rate was 38%; for those with inade- comes were grouped by the eradication of the pathogen, quate therapy, the mortality rate was 91%.
the continued isolation of the pathogen, or the emergence After bronchoscopy was completed, 42 of the 65 pa- of a new pathogen. Any pathogens present on the repeat tients (65%) received adequate therapy and the other 23 bronchoscopy were noted as being at low (ie, ⬍ 103 received inadequate therapy, but the mortality rate in the cfu/mL) or high (ie, ⱖ 103 cfu/mL) concentrations.
two groups was comparable. Similarly, outcomes did not In the study by Montravers et al32, 51 patients had improve after bronchoscopic data were known, although sterile pulmonary secretions by day 3, 16 patients had almost all patients received adequate therapy at that time.
persistent low-level infection, and 9 patients had persistent The generalizability of these findings is limited by the very high-level infection (Table 23). Clinical improvement was high mortality rates reported by Luna et al33 in all patient seen in 96% of those with microbiological eradication, in groups. Bronchoscopy may identify organisms that are not 81% of those with persistent low-level infection, and in responding to the initial antibiotic regimen. Whether this 44% of those with persistent high-level infection information will improve the outcome is uncertain but (p ⬍ 0.01).
needs to be formally investigated.
Follow-up bronchoscopy can be used to identify pa- Recently Rello et al132 studied 113 patients with VAP, tients with a clinical nonresponse to therapy. The highest 100 of whom (88%) had an organism identified by bron- rates of clinical nonresponse occurred in the patient whose choscopy. Based on these data, 27 patients had initial follow-up bronchoscopy showed a high concentration of inadequate antibiotic therapy. This group had a signifi- bacteria. The finding of persistent bacterial infection can cantly higher mortality rate than those receiving adequate be used to predict a poor outcome, but there are no data therapy (37% vs 15.4%, respectively). However, when to suggest that interventions based on these results will antibiotic therapy was changed, based on bronchoscopic improve patient outcome.
data, 17 of the 27 patients (63%) had clinical resolution,and 10 of those 17 patients (59%) survived and weredischarged. Thus, bronchoscopically directed changes in Are Serial Bronchoscopy Data Likely to therapy may have been beneficial, although aspiration Help the Nonresponding Patient? cultures may have provided similar data.
The potential limitations of serial bronchoscopy include The results of the study by Montravers et al32 suggest the following: (1) information may become available too that data taken from serial PSB sampling provide a late; (2) the bacteriologic information could be provided microbiological explanation for clinical nonresponse.
by simpler, more readily available methods, such as tra- However, it is uncertain whether this information leads to cheal aspiration culture; and (3) repeat testing usually improved outcome. The outcome in patients with nosoco- isolates highly resistant organisms that would not be mial pneumonia may be dictated by the efficacy of initial eliminated by changes in antibiotic therapy. The last therapy. Bronchoscopic data may be available too late to limitation was suggested by Garrard and A'Court,131 who influence the course of illness.
found that nonresponding patients had persistent high- Luna et al33 used bronchoscopy with quantitative BAL level infections with organisms that are difficult to eradi- and found an etiologic pathogen in 65 of 132 patients cate, such as P aeruginosa. Similarly, Silver et al133 de- (49%) who had a clinical diagnosis of nosocomial pneu- scribed the phenomenon of recurrent infection with monia. More than half of the patients were already P aeruginosa in critically ill patients. Silver et al133 docu- receiving antibiotics for either community-acquired pneu- mented that recurrent infection with this organism is monia or a previous episode of nosocomial pneumonia. In common (ie, found in 10 of 20 patients [50%] who this group, 50 of the 65 patients (77%) received immediate survived a first episode of P aeruginosa pneumonia) and antibiotic therapy, prior to the bronchoscopy, which was often fatal (mortality rate, 60% for those patients with performed within 24 h after the clinical diagnosis of recurrent P aeruginosa pneumonia vs 10% for those pneumonia. For 16 of 65 patients (25%) whose initial therapy was adequate (as defined by BAL bacteriology Souweine and colleagues36 confirmed that bronchos- Evidence-Based Assessment of Diagnostic Tests for Ventilator-Associated Pneumonia copy can identify the bacteria responsible for nonresponse infection during the acute respiratory distress syndrome.
to therapy in patients with VAP. When bronchoscopy was Am J Respir Crit Care Med 1995; 152:550 –556 performed in 31 patients who had received antibiotic 13 El-Ebiary M, Torres A, Gonzalez J, et al. Quantitative therapy for ⬎ 72 h, diagnostic sensitivity was 83% for BAL cultures of endotracheal aspirates for the diagnosis of venti- and 77% for PSB. Of the 15 organisms isolated, 11 were lator-associated pneumonia. Am Rev Respir Dis 1993; 148: resistant to the current antibiotic, suggesting that bron- 14 Sauaia A, Moore F, Moore E, et al. Diagnosing pneumonia in choscopy can document the presence of persistent and mechanically ventilated trauma patients: endotracheal aspi- resistant pathogens in patients not responding to therapy.
rate versus bronchoalveolar lavage. J Trauma 1993; 35:512–517 15 Torres A, Puig de la Bellacasa J, Xaubet A, et al. Diagnostic value of quantitative cultures of bronchoalveolar lavage andtelescoping plugged catheters in mechanically ventilated pa- • The impact of repeated quantitative cultures (broncho- tients with bacterial pneumonia. Am Rev Respir Dis 1989; scopic or nonbronchoscopic) on the outcomes of pa- tients with VAP has been incompletely studied.
16 Lambert R, Vereen L, George R. Comparison of tracheal • Serial microbiological diagnostic studies in VAP patients aspirates and protected brush catheter specimens for identi- may identify those at increased risk for mortality.
fying pathogenic bacteria in mechanically ventilated patients.
• With invasive techniques, the persistent recovery of Am J Med Sci 1989; 297:377–382 high concentrations of potential pathogens identifies 17 Shepherd K, Lynch J, Brown E, et al. Elastin fibers and the diagnosis of bacterial pneumonia in adult respiratory distress patients at high risk for mortality.
syndrome. Crit Care Med 1995; 23:1829 –1834 There are insufficient data to show that repeated bron- 18 Marquette C, Copin M, Wallet F, et al. Diagnostic tests for choscopy affects the survival rate of patients who did not pneumonia in ventilated patients: prospective evaluation of respond to initial therapy.
diagnostic accuracy using histology as a diagnostic goldstandard. Am J Respir Crit Care Med 1995; 151:1878 –1888 19 Sole´-Viola´n J, Rodriguez de Castro F, Rey A, et al. Compar- ison of bronchoscopic diagnostic techniques with histological findings in brain dead organ donors without suspected pneu- 1 Wimberly N, Faling L, Bartlett J. A fiberoptic bronchoscopy monia. Thorax 1996; 51:929 –931 technique to obtain uncontaminated lower airway secretions 20 Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind for bacterial culture. Am Rev Respir Dis 1979; 119:337–343 sampling techniques for the diagnosis of ventilator-associated 2 Niedermann M, Torres A, Summer W. Invasive diagnostic pneumonia. Am J Respir Crit Care Med 1995:1982–1991 testing is not needed routinely to manage suspect ventilator- 21 Timsit J-F, Misset B, Goldstein F, et al. Reappraisal of distal associated pneumonia. Am J Respir Crit Care Med 1994:565– diagnostic testing in the diagnosis of ICU-acquired pneumo- nia. Chest 1995; 108:1632–1639 3 Chastre J, Fagon J. Invasive diagnostic testing should be 22 Valle´s J, Rello J, Fernandez R, et al. Role of bronchoalveolar routinely used to manage ventilated patients with suspected lavage in mechanically ventilated patients with suspected pneumonia. Am J Respir Crit Care Med 1994:570 –574 pneumonia. Eur J Clin Microbiol Infect Dis 1994; 13:549 – 4 Kollef M. Ventilator-associated pneumonia. JAMA 1993; 23 Torres A, Martos A, Puig de la Bellacasa J, et al. Specificity of 5 American Thoracic Society. Hospital-acquired pneumonia in endotracheal aspiration, protected specimen brush, and bron- adults: diagnosis, assessment of severity, initial antimicrobial choalveolar lavage in mechanically ventilated patients. Am therapy, and preventative strategies. Am J Respir Crit Care Rev Respir Dis 1993; 147:952–957 Med 1995; 153:1711–1725 24 Chastre J, Fagon J, Soler P, et al. Diagnosis of nosocomial 6 Fagon J, Chastre J, Hance A, et al. Nosocomial pneumonia in bacterial pneumonia in intubated patients undergoing venti- ventilated patients: a cohort study evaluating attributable lation: comparison of the usefulness of bronchoalveolar lavage mortality and hospital stay. Am J Med 1993; 94:281–288 and the protected specimen brush. Am J Med 1988; 85:499 – 7 Boyce J, Potter-Bynoe G, Dziobek L, et al. Nosocomial pneumonia in Medicare patients: hospital costs and reim- 25 Montravers P, Gauzit R, Dombret M, et al. Cardiopulmonary bursement patterns under the prospective payment system.
effects of bronchoalveolar lavage in critically ill patients.
Arch Intern Med 1991; 151:1109 –1114 Chest 1993; 104:1541–1547 8 Wunderink R, Woldenberg L, Zeiss J, et al. Radiologic 26 Baughman R, Thorpe J, Staneck J, et al. Use of the protected diagnosis of autopsy-proven ventilator-associated pneumonia.
specimen brush in patients with endotracheal or tracheos- Chest 1992; 101:458 – 463 tomy tubes. Chest 1987; 91:233–236 9 Winer-Muram H, Rubin S, Ellis J, et al. Pneumonia, and 27 Marquette C, Herengt F, Mathieu D, et al. Diagnosis of ARDS. in patients receiving mechanical ventilation: Diagnos- pneumonia in mechanically ventilated patients: repeatability tic accuracy of chest radiography. Radiology 1993; 188:479 – of the protected specimen brush. Am Rev Respir Dis 1993; 10 Lefcoe M, Fox G, Leasa D. Accuracy of portable chest 28 Timsit J-F, Misset B, Renaud, et al. Effect of previous radiography in the critical care setting: diagnosis of pneumo- antimicrobial therapy on the accuracy of the main procedures nia based on quantitative cultures obtained from protected used to diagnose nosocomial pneumonia in patients who are brush catheter. Chest 1994; 105:885– 887 using ventilation. Chest 1995; 108:1036 –1040 11 Fagon J, Chastre J, Hance A. Evaluation of clinical judgment 29 Chastre J, Viau F, Brun P, et al. Prospective evaluation of the in the identification and treatment of nosocomial pneumonia protected specimen brush for the diagnosis of pulmonary in ventilated patients. Chest 1993; 103:547–553 infections in the ventilated patients. Am Rev Respir Dis 1984; 12 Sutherland K, Steinberg K, Maunder R, et al. Pulmonary CHEST / 117 / 4 / APRIL, 2000 SUPPLEMENT 30 Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator- 48 Horan T, Culver D, Jarvis, et al. Pathogens causing nosoco- associated pneumonia by bacteriologic analysis of broncho- mial infections. CDC Antimicrobe Newsletter 1988:65– 67 scopic and nonbronchoscopic "blind" bronchoalveolar lavage 49 Tablan O, Anderson L, Arden N, et al. Guideline for preven- fluid. Am Rev Respir Dis 1991; 143:1121–1129 tion of nosocomial pneumonia: Part 1. Issues on prevention of 31 Marik P, Brown W. A comparison of bronchoscopic vs blind nosocomial pneumonia. Infect Control Hosp Epidemiol protected speciman brush sampling in patients with sus- 1994; 15:588 – 625 pected ventilator-associated pneumonia. Chest 1995; 108: 50 Weinstein R. Epidemiology and control of nosocomial infec- tions in adult intensive care units. Am J Med 1991; 91:3B- 32 Montravers P, Fagon J, Chastre J, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumo- 51 Prod'hom G, Leuenberger P, Koerfer J, et al. Nosocomial nia. Am Rev Respir Dis 1993; 147:38 – 44 pneumonia in mechanically ventilated patients receiving ant- 33 Luna C, Vujacich P, Niederman M, et al. Impact of BAL data acid, ranitidine, or sucralfate as prophylaxis for stress ulcer.
on the therapy and outcome of ventilator associated pneumo- Ann Intern Med 1994; 120:653– 662 nia. Chest 1997; 111:676 – 685 52 Reusser P, Zimmerli W, Scheidegger D, et al. Role of gastric 34 Sanchez-Nieto J, Torres A, Garcia-Cordoba F, et al. Impact colonization in nosocomial infections and endotoxemia: a of invasive and non-invasive quantitative culture sampling on prospective study in neurosurgical patients on mechanical outcome of ventilator-associated pneumonia. Am J Respir ventilation. J Infect Dis 1989; 60:414 – 421 Crit Care Med 1998; 157:371–376 53 Valle´s J, Artigas A, Rello, et al. Continuous aspiration of 35 Bonten M, Bergmans D, Stobberingh E, et al. Implementa- subglottic secretions in preventing ventilator-associated tion of bronchoscopic techniques in the diagnosis of ventila- pneumonia. Ann Intern Med 1995; 122:179 –186 tor-associated pneumonia to reduce antibiotic use. Am J 54 Schleupner C, Cobb D. A study of the etiologies and Respir Crit Care Med 1997; 156:1820 –1824 treatment of nosocomial pneumonia in a community-based 36 Souweine B, Verber B, Bedos J, et al. Diagnostic accuracy of teaching hospital. Infect Control Hosp Epidemiol 1992; protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: impact of previous antimicrobial 55 Dal Nogare A. Nosocomial pneumonia outside the intensive treatments. Crit Care Med 1998; 26:236 –244 care unit. In: Niederman MS, Sarosi GA, Glassroth J, eds.
37 Rouby J, Rossignon M, Nicholas M, et al. A prospective study Respiratory infections. Philadelphia, PA: WB Saunders, 1994; of protected bronchoalveolar lavage in the diagnosis of nos- ocomial pneumonia. Anesthesiology 1989; 71:679 – 685 56 Maki D. Control of colonization and transmission of patho- 38 Bell R, Coalson J, Smith J, et al. Multiple organ system failure genic bacteria in the hospital. Ann Intern Med 1978; 89:777– and infection in adult respiratory distress syndrome. Ann Intern Med 1983; 99:293–298 57 Inglis T, Sproat L, Hawkey P, et al. Staphylococcal pneumo- 39 Andrews C, Coalson J, Smith J. Diagnosis of nosocomial nia in ventilated patients: a twelve month review of cases in an bacterial pneumonia in acute, diffuse lung injury. Chest 1981; intensive care unit. J Hosp Infect 1993; 25:207–210 58 Rello J, Torres A, Ricart M, et al. Ventilator-associated 40 Fagon J, Chastre J, Hance A, et al. Detection of nosocomial pneumonia by Staphylococcus aureus: comparison of methi- lung infection in ventilated patients: use of a protected cillin-resistant and methicillin-sensitive episodes. Am J Respir specimen brush and quantitative culture techniques in 147 Crit Care Med 1994; 150:1545–1549 patients. Am Rev Respir Dis 1988; 138:110 –116 59 Craven D, Reed C, Kollisch N, et al. A large outbreak of 41 Torres A, El-Ebiary M, Padro´ L, et al. Validation of different infections caused by a strain of Staphylococcus aureus resis- techniques for the diagnosis of ventilator-associated pneumo- tant to oxacillin and aminoglycosides. Am J Med 1981; nia: comparison with immediate postmortem pulmonary bi- opsy. Am J Respir Crit Care Med 1994; 149:324 –331 60 Dreyfuss D, Mier L, Le Bordelles G, et al. Clinical signifi- 41aSackett DL, Richardson WS, Rosenberg W, et al. Evidence- cance of borderline quantitative protected specimen culture based medicine. how to practice and teach EBM. New York, results. Am Rev Respir Dis 1993; 147:946 –951 NY: Churchill Livingstone, 1997; 124 –125 61 Hanson L, Weber D, Rutala, et al. Risk factors for nosocomial 42 Rodriguez de Castro F, Sole´ J, Elcuaz R. Quantitative pneumonia in the elderly. Am J Med 1992; 92:161–166 cultures of protected brush specimens and bronchoalveolar 62 Celis R, Torres A, Gatell J, et al. Nosocomial pneumonia: a lavage in ventilated patients without suspected pneumonia.
multivariate analysis of risk and prognosis. Chest 1988; Am J Respir Crit Care Med 1994; 149:320 –332 43 Fagon J, Chastre J, Domart Y, et al. Nosocomial pneumonia 63 Cross A, Roup B. Role of respiratory assistance devices in in patients receiving continuous mechanical ventilation: pro- endemic nosocomial pneumonia. Am J Med 1981; 70:681–685 spective analysis of 52 episodes with use of a protected 64 Haley R, Hooton T, Culver D, et al. Nosocomial infections in specimen brush and quantitative culture techniques. Am Rev U.S. hospitals, 1975–1976: estimate frequency by selected Respir Dis 1989; 139:877– 884 characteristics of patients. Am J Med 1981; 70:947–959 44 Torres A, Aznar R, Gatell J, et al. Incidence, risk, and 65 Langer M, Mosconi P, Cigada M, et al. Long-term respiratory prognosis factors of nosocomial pneumonia in mechanically support and risk of pneumonia in critically ill patients. Am ventilated patients. Am Rev Respir Dis 1990; 142:523–528 Rev Respir Dis 1989; 140:302–305 45 Torres A, Puig de la Bellacasa J, Rodriguez Roisin R, et al.
66 George D. Epidemiology of nosocomial ventilator-associated Diagnostic value of telescoping plugged catheters in mechan- pneumonia. Infect Control Hosp Epidemiol 1993; 14:163– ically ventilated patients with bacterial pneumonia using the Metras catheter. Am Rev Respir Dis 1988; 138:117–120 67 Craven D, Kunches L, Kilinsky V, et al. Risk factors for 46 Bartlett J, O'Keefe P, Tally F, et al. Bacteriology of hospital- pneumonia and fatality in patients receiving continuous me- acquired pneumonia. Arch Intern Med 1986; 146:868 – 871 chanical ventilation. Am Rev Respir Dis 1986; 133:792–796 47 Rello J, Quintana E, Ausina V, et al. Incidence, etiology, and 68 Rhame F, Streifel A, Kersey J, et al. Extrinsic risk factors for outcome of nosocomial pneumonia in mechanically ventilated pneumonia in the patient at high risk for infection. Am J Med patients. Chest 1991; 100:439 – 444 Evidence-Based Assessment of Diagnostic Tests for Ventilator-Associated Pneumonia 69 Driks M, Craven D, Celli B, et al. Nosocomial pneumonia in tools. Am J Respir Crit Care Med 1996; 154:116 –123 intubated patients given sucralfate as compared with antacids 90 Sterling T, Ho E, Brehm W. Diagnosis and treatment of or histamine type 2 blockers: the role of gastric colonization.
ventilator-associated pneumonia-impact on survival. Chest N Engl J Med 1987; 317:1376 –1382 1996; 110:1025–1034 70 Chevret S, Hemmer M, Carlet J, et al. Incidence and risk 91 Hill J, Ratliff J, Parrott J, et al. Pulmonary pathology in acute factors of pneumonia acquired in intensive care units. Inten- respiratory insufficiency: lung biopsy as a diagnostic tool.
sive Care Med 1993; 19:256 –264 J Thorac Cardiovasc Surg 1976; 71:64 –71 71 Kirby B, Snyder K, Meyer R, et al. Legionnaires' disease: 92 Baigelman W, Bellin S, Cupples A, et al. Bacterologic report of sixty-five nosocomially acquired cases and review of assessment of the lower respiratory tract in intubated pa- the literature. Medicine 1980; 59:188 –205 tients. Crit Care Med 1986; 14:864 – 868 72 Jarvis W, Edwards J, Culver D, et al. Nosocomial infection 93 Middleton R, Broughton W, Kirkpatrick M. Comparison of rates in adult and pediatric intensive care units in the United four methods for assessing airway bacteriology in intubated States. Am J Med 1991; 91(suppl 3B):185S–191S mechanically ventilated patients. Am J Med Sci 1992; 73 Lareau S, Ryan K, Diener C. The relationship between frequency of ventilator circuit changes and infectious hazard.
94 Jourdain B, Novara A, Joly-Guillou M, et al. Role of Am Rev Respir Dis 1978; 118:493– 496 quantitative cultures of endotracheal aspirates in the role of 74 Graybill J, Marshall L, Charache P, et al. Nosocomial pneu- nosocomial pneumonia. Am J Respir Crit Care Med 1995; monia: a continuing major problem. Am Rev Respir Dis 1973; 95 Marquette C, Georges H, Wallett F, et al. Diagnostic 75 Gross P, Neu H, Aswapokee P, et al. Deaths from nosocomial efficiency of endotracheal aspirates with quantitative bacte- infections: experience in a university hospital and a commu- rial cultures in intubated patients with suspected pneumo- nity hospital. Am J Med 1980; 68:219 –223 nia. Am Rev Respir Dis 1993; 148:138 –144 76 Freeman J, Rosner B, McGowan J. Adverse effects of noso- 96 Villers D, Derriennic M, Raffi F, et al. Reliability of the comial infection. J Infect Dis 1979; 140:732–740 bronchoscopic protected catheter brush in intubated and 77 Craven D, Steger K, Fleming C. Preventing hospital-acquired ventilated patients. Chest 1985; 88:527–530 pneumonia: current concepts and strategies. Semin Respir 97 Torres A, El-Ebiary M, Fa bregas N, et al. Value of intrac- Crit Care Med 1997; 18:85–200 ullular bacteria detection in the diagnosis of ventilator- 78 Daschner F, Nadjem H, Langmaack H, et al. Surveillance, associated pneumonia. Thorax 1996; 51:378 –384 prevention and control of hospital-acquired infections: III.
98 Barreiro B, Dorca J, Manresa F, et al. Protected bronchoal- Nosocomial infections as cause of death: retrospective analy- veolar lavage in the diagnosis of ventilator-associated pneu- sis of 1,000 autopsy reports. Infection 1978; 6:261–265 monia. Eur Respir J 1996; 9:1500 –1507 79 Craig C, Connelly S. Effect of intensive care unit nosocomial 99 Chastre J, Fagon J, Bornet-Lecso M, et al. Evaluation of pneumonia on duration of stay and mortality. Am J Infect bronchoscopic techniques for the diagnosis of nosocomial Control 1984; 12:233–238 pneumonia. Am J Respir Crit Care Med 1995; 152:231–240 80 Baker A, Meredeth J, Haponik E. Pneumonia in intubated 100 Meduri G, Wunderink R, Leeper K. Management of bacte- trauma patients: microbiology and outcomes. Am J Respir rial pneumonia in ventilated patients: protected bronchoal- Crit Care Med 1996; 153:343–349 veolar lavage as a diagnostic tool. Chest 1992; 101:500 –508 81 Papazian L, Bregeon F, Thirion X, et al. Effect of ventilator- 101 Meduri G, Beals D, Maijub A, et al. Protected bronchoal- associated pneumonia on mortality and morbidity. Am J veolar lavage: a new bronchoscopic technique to retrieve Respir Crit Care Med 1996; 154:91–97 uncontaminated distal airway secretions. Am Rev Respir Dis 82 Leu H, Kaiser D, Mori M, et al. hospital-acquired pneumo- 1991; 143:855– 864 nia: attributable mortality and morbidity. Am J Epidemiol 102 Guerra L, Baughman R. Use of bronchoalveolar lavage to 1989; 129:1258 –1267 diagnose bacterial pneumonia in mechanically ventilated 83 Meduri G, Mauldin G, Wunderink R, et al. Causes of fever patients. Crit Care Med 1990; 18:169 –173 and pulmonary densities in patients with clinical manifesta- 103 Sole´-Viola´n J, Rodriguez de Castro F, Rey A, et al. Useful- tions of ventilator-associated pneumonia. Chest 1994; 106: ness of microscopic examination of intracellular organisms in lavage fluid in ventilator-associated pneumonia. Chest 1994; 84 Rouby J, De Lassale E, Poete P, et al. Nosocomial broncho- pneumonia in the critically Ill. Am Rev Respir Dis 1992; 104 Aubas S, Aubas P, Capdevila X, et al. Bronchoalveolar lavage for diagnosing bacterial pneumonia in mechanically venti- 85 Meduri G, Chastre J. The standardization of bronchoscopic lated patients. Am J Respir Crit Care Med 1994; 149:860 – techniques for ventilator-associated pneumonia. Chest 1992; 105 Steinberg K, Mitchell D, Maunder R, et al. Safety of 86 Beydon L, Saada M, Liu N, et al. Can portable chest x-ray bronchoalveolar lavage in patients with adults respiratory examination accurately diagnose lung consolidation after ma- distress syndrome. Am Rev Respir Dis 1993; 148:556 –561 jor abdominal surgery?: a comparison with computed tomog- 106 Herna´ndez C, El-Ebiary M, Torres A, et al. Side-effects of raphy scan. Chest 1992; 102:1698 –1703 two different types of protected bronchoalveolar lavage in 87 Ely E, Johnson M, Chiles C, et al. Chest x-ray changes in air mechanically ventilated patients [abstract]. Am J Respir Crit space disease are associated with parameters of mechanical Care Med 1997; 155(Suppl):A397 ventilation in ICU patients. Am J Respir Crit Care Med 1996; 107 Pugin J, Suter P. Diagnostic bronchoalveolar lavage in patients with pneumonia produces sepsis-like systemic ef- 88 Torres A, Serra-Batles J, Ros E, et al. Pulmonary aspiration of fects. Intensive Care Med 1992; 18:6 –10 gastric contents in patients receiving mechanical ventilation: 108 Wunderink R, Mayhall C, Gibert C. Methodology for the effect of body position. Ann Intern Med 1992; 116:540 – clinical investigation of ventilator-associated pneumonia: epidemiology and therapeutic intervention. Chest 1992(suppl); 89 Timsit J-F, Chevret S, Valcke J, et al. Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic 109 Marquette C, Wallet F, Neviere R, et al. Diagnostic value of CHEST / 117 / 4 / APRIL, 2000 SUPPLEMENT direct examination of the protected specimen brush in 122 Papazian L, Martin C, Meric B, et al. A reappraisal of blind ventilator-associated pneumonia. Eur Respir J 1994; 7:105– bronchial sampling in the microbiologic diagnosis of noso- comial bronchopneumonia: a comparative study in venti- 110 Teague R, Wallace R, Awe R. The use of quantitative sterile lated patients. Chest 1993; 103:236 –242 brush culture and Gram stain analysis in the diagnosis of 123 Leal-Noval S, Alfaro-Rodriguez E, Murillo-Cabeza F, et al.
lower respiratory tract infections. Chest 1981; 79:157–161 Diagnostic value of the blind brush in mechanically venti- 111 Wimberly N, Faling L, Bartlett J. A fiberoptic bronchoscopy lated patients with nosocomial pneumonia. Intensive Care technique to obtain uncontaminated lower airway secretions Med 1992; 18:410 – 414 for bacterial culture. Am Rev Respir Dis 1979; 119:337–343 124 Gaussorgues P, Piperno D, Bachmann P, et al. Comparison 112 Keely S, Pai H, Baughman R, et al. Pneumocystis species of nonbronchoscopic bronchoaveolar lavage to open lung inferred from analysis of multiple genes. J Eukaryot Micro- biopsy for bacteriologic diagnosis of pulmonary infections in biol 1994; 41(suppl):94S mechanically ventilated patients. Intensive Care Med 1989; 113 Baselski V, El-Torky M, Coalson J, et al. The standardization of criteria for processing and interpreting laboratory speci- 125 Jorda R, Parras F, Ibanez J. Diagnosis of nosocomial mens in patients with suspected ventilator-associated pneu- pneumonia in mechanically ventilated patients by the blind monia. Chest 1992; 102(suppl):571S–579S protected telescoping catheter. Intensive Care Med 1993; 114 Bassin A, Niederman M. Prevention of ventilator-associated pneumonia: an attainable goal? Clin Chest Med 1995; 126 A'Court C, Garrard C, Crook D. Microbiological lung surveillance in mechanically ventilated patients, using non- 115 Timsit J-F, Misset B, Francoual, et al. Is protected specimen directed bronchial lavage and quantitative culture. Q J Med brush a reproducible method to diagnose ICU-acquired 1993; 86:635– 648 pneumonia? Chest 1993; 104:104 –108 127 Kollef M, Silver P, Murphy D, et al. The effect of late-onset 116 Sole´-Viola´n J, Rodriguez de Castro F, Caminero Luna J, et ventilator-associated pneumonia in determining patient al. Comparative efficacy of bronchoalveolar lavage and mortality. Chest 1995; 108:1655–1662 telescoping plugged catheter in the diagnosis of pneumonia 128 Rello J, Ausina V, Ricart M, et al. Impact of previous in mechanically ventilated patients. Chest 1993; 103:386 – antimicrobial therapy on the etiology and outcome of ven- tilator-associated pneumonia. Chest 1993; 104:1230 –1235 117 Richard C, Pezzano M, Bouhaja B, et al. Comparison of 129 Malangoni M, Crafton R, Mocek F. Pneumonia in the non-protected lower respiratory tract secretions and pro- surgical intensive care unit: Factors determining successful tected specimen brush samples in the diagnosis of pneumo- outcome. Am J Surg 1994; 167:250 –255 nia. Intensive Care Med 1988; 14:30 –33 130 Rello J, Jubert P, Valle´s J, et al. Evaluation of outcome for 118 Marquette C, Herengt F, Saulnier F, et al. Protected intubated patients with pneumonia due to Pseudomonas specimen brush in the assessment of ventilator-associated aeruginosa. Clin Infect Dis 1996; 23:973–978 pneumonia: selection of a certain lung segment for bron- 131 Garrard C, A'Court C. The diagnosis of pneumonia in the choscopic sampling is unnecessary. Chest 1993; 103:243– critically ill. Chest 1995; 108(suppl):17S–25S 132 Rello J, Gallego M, Mariscal D, et al. The value of routine 119 Kollef M, Bock K, Richards R, et al. The safety and microbial investigation in ventilator-associated pneumonia.
diagnostic accuracy of minibronchoalveolar lavage in pa- Am J Respir Crit Care Med 1997; 156:196 –200 tients with suspected ventilator-associated pneumonia. Ann 133 Silver D, Cohen I, Weinberg P. Recurrent Pseudomonas. Intern Med 1995; 122:743–748 aeruginosa pneumonia in an intensive care unit. Chest 1992; 120 Pham L, Brun-Buisson C, Legrand P, et al. Diagnosis of nosocomial pneumonia in mechanically ventilated patients.
134. Wunderink RG, Russell GB, Mezger E, et al. The diagnos- Am Rev Respir Dis 1991; 143:1055–1061 tic utility of the antibody-coated bacteria test in intubated 121 Papazian L, Martin C, Albanese J, et al. Comparison of two patients. Chest 1991; 99:84 – 88 methods of bacteriologic sampling of the lower respiratory 135. Salata RA, Lederman MM, Shlaes DM, et al. Diagnosis of tract: a study in ventilated patients with nosocomial bron- nosocomial pneumonia in intubated, intensive care unit chopneumonia. Crit Care Med 1989; 17:461– 464 patients. Am Rev Respir Dis 1987; 135:426 – 432 Evidence-Based Assessment of Diagnostic Tests for Ventilator-Associated Pneumonia

Source: http://idd00pgh.eresmas.net/guidelines/212S.pdf

Targeted nutritional intervention für down-syndrom

Targeted Nutritional Intervention für Down-Syndrom Vortrag anlässlich der insieme 21 Tagung mit Schwerpunktthema Ernährung und Nahrungsergänzung in Zug am 15.11.08 (Letzte Aktualisierung: November 2010) Autor: Richard Müller, Zürich • Was ist TNI? • Ginkgo Biloba, Fischöl, Probiotika, Vitamin D und Curcumin

Microsoft word - lidia brunetto's phd thesis.doc

Università degli Studi di Catania Scuola Superiore di Catania International PhD Investigation of Cancer Stem Cells (CSCs)-derived exosomes and their influence on the tumor microenvironment Coordinator of PhD Tutor Prof. Daniele Condorelli Prof. Ruggero De Maria a.a. 2008/2011 Agli uomini della mia vita Valerio e Riccardo